Fosun Pharma's 3 innovative drugs have been approved for clinical lyxidan resistance and are expected to challenge Roche

Recently, Fosun Pharma has issued a series of clinical announcements of the approval of products, including the recombinant anti-VEGFR2 all-human monoclonal antibody injection of subsidiary Fuhong Hanxuan, subsidiary Chongqing Fuxing and Fushan Huizhen FCN-437c capsules, subsidiary Fosun Pharmaceutical Industry and Xingtai Pharma injection FN-1501. In addition, it is worth mentioning that on 29 January Fosun Pharma's lytoxidan anti-injection was included in the priority review and is expected to become the first biosypolytic drug in the country. For Fosun, the recent ups and women have been good news.3 products approved for clinical
Since 2018, Fosun Pharma has approved three drugs, including the recently popular recombinant anti-VEGFR2 all-human monoclonal antibody injection, as well as FCN-437c capsules, injection FN-1501 two class 1 chemicals.
recombinant anti-VEGFR2 all-human monoclonal antibody injection, for the company's own research and development of innovative therapeutic biological products, mainly used in solid tumor treatment. As of this announcement date, the world-listed VEGFR2 target monoclonal antibody drug is only Lilly's Ramucirumab, while no similar drugs of the same target have been listed in China (excluding Hong Kong, Macao and Taiwan). According to Minenet, reed-resistant global sales reached $614 million in 2016.
FCN-437c capsule, for the company's own research and development of small molecule innovative drugs, mainly used in solid tumor treatment. As of the date of this announcement, there are no drugs with independent intellectual property rights in China (excluding Hong Kong, Macao and Taiwan) that are on the same target as the new drug.
injection FN-1501, for the company by the Chinese Pharmaceutical University transfer, follow-up independent research and development of innovative small molecule chemical drugs, mainly used in leukemia treatment. As of the date of this announcement, there are no drugs with independent intellectual property rights in China (excluding Hong Kong, Macao and Taiwan) on the market with the same target as the new drug, and the new drug with the same target will be listed in the United States for the first time in 2017.Litoxi single anti-listing sprint, grab the domestic market of more than 2 billion
According to the third-quarter report disclosed that Fosun Pharma in the first three quarters of 2017 the company's research and development expenses reached 700 million yuan, up 46% YoY. Fosun Pharma said the change in research and development costs was mainly due to continued increased investment in research and development of monoclonal antibody bioinnovatants and biosynthics, small molecule innovative drugs, and a centralized investment in consistent evaluation during the reporting period.
Fusun Pharmaceuticals mono-anti-drug layout complete, similar drug series is in the forefront of the domestic. Lytoxi monoantigen injection (recombinant human mouse embedded anti-CD20 monoclonal antibody injection) is Fosun Pharma's independent research and development of large-molecule biosynthetic drugs, mainly applicable to non-Hodgkin's lymphoma, rheumatoid arthritis treatment. On January 29, the CDE announced that it intends to include drug registration applications for inclusion in the priority review process (26th batch), and Fosun Pharma's "Lytoxi single anti-injection" listing application was included in the priority review publicity list, which means that the domestic first biosychlic drug market into the final sprint stage. At present, the domestic listing of lysoxi single anti-injection only Shanghai Roche Pharmaceutical Co., Ltd.'s Merivale. According to Milnet data, in 2016 China's public medical institutions terminal Melohua sales reached 2.43 billion yuan.
In addition, the company's qutoju single anti-recombinant anti-HER2 human monoclonal antibody), Adamo monoantigen (recombinant anti-TNF alpha all-human monoclonal antibody injection) is in phase III clinical stage, is expected to submit a listing application in 2018, approved for listing in 2019; Humanized monoclonal antibody) non-small cell lung cancer Phase I clinical, WAMD clinical trial application was accepted, small molecule innovative drugs have also been approved clinical, compoundininib, FCN-411, PA-824 and other varieties in Phase I clinical, FC-102, FN-1501 approved clinical.products cover six major disease areas
In the first half of 2017, Fosun Pharma achieved revenue of 83.530226 million yuan, an increase of 20.41% over the same period in 2016, of which the pharmaceutical manufacturing and research and development business achieved revenue of 577.57788 million yuan, an increase of 19.12% over the same period in 2016, accounting for 69.15% of total revenue.
Fosun Pharma has a rich product line in the six most promising disease areas of China's pharmaceutical market (cardiovascular, metabolic and digestive systems, central nervous system, blood system, anti-infection, anti-tumor), with sales of key core products growing rapidly and leading the market segments.
Core products in the field of cardiovascular disease treatment include prostyl cogan milk (Udir), heparin series preparations, injection cyclophosphate glucosamine (cardiac), calcium hydroxybenzene (cocoa), timishatan tablets (Bontan), and Pyvastatin (bon).
The core products in the field of metabolic and digestive disease treatment include also prototype glutathione series (Atomolan needle, atomolan tablets), non-busta tablets (Ulyton), Gremethal tablets (Wan Suping), animal insulin and its preparations, recombinant human erythrocytoglycline (Yibao), compound aloe vera capsules. According to Milnet data, in 2016 China's public medical institutions terminal, Chongqing Pharmaceuticals Pharmaceuticals (Fosun Pharmaceutical Holdings subsidiary) also produced prototype glutathione sales of up to 1.1 billion yuan, the market share ranked first.
core products in the field of treatment of diseases of the central nervous system include calf serum deprotein injections (Odekin), fumarate sulphate tablets (kaiwei).
core products in the field of disease treatment of the blood system include white-brow snake venom (Bontin), injection adenosine cobaltamine (Milaka).
core products in the field of anti-infective disease treatment include artemisinin and other antimalarial series, anti-tuberculosis series, cephalosporine preparations (Se chang, pioneer methamphetol), injectable antonin (shadolica), sodium saba Tan sodium 1.5g (strong Shuxilin), pirasilin sodium Shubatan sodium 3g (yushu), pyracirin sodium tazepam sodium (sulphasilin), cephalosporinesodium (di leaf bi).
core products in the field of anti-tumor disease treatment include west yellow capsules, injectable pyrethroid sodium (iroze), and picaroamine (assailant).
and intermediate core products include amino acid series, amino acid, hydrochloric acid Klinmycin.
It is worth mentioning that the company's cardiovascular system disease treatment field of pivartatin (Bang) and the forefront of dry milk (Udier), metabolic and digestive system disease treatment collar of the compound aloe vera capsules and non-busta tablets (Ultong), anti-tumor disease treatment core products such as Pemite tazer (Iroze) has been selected in the "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog" (2017 edition). results grew steadily
Fosun Pharma's revenue for the first three quarters of 2017 was RMB12,960 million, up 21.83 percent year-on-year, and its net profit was RMB2,419 million, up 11.13 percent year-on-year.
Pharmaceutical manufacturing is Fosun Pharma's main business, the core varieties of pivastatin, forefront of dry milk, non-busta, Pyme qusser second sodium into the 2017 health insurance catalog, is expected to accelerate the release, further thicken the company's performance; To consolidate the strategic layout of the combination of high-end medical care, second- and third-tier urban specialties and general hospitals in developed coastal cities, the company has established a joint venture with Leonardo da Vinci Robotics to deeply participate in the medical robot industry chain, and Sisram, a subsidiary of Medical Andi Devices, has successfully landed in H-shares, and business expansion is expected to accelerate. (Mi net)